1. Executive Summary
1.1. Global Gene Therapy Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Gene Therapy Market Outlook, 2018 - 2030
3.1. Global Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Non-viral Vectors
3.1.1.1.1. Oligonucleotides
3.1.1.1.2. Other Non-viral Vectors
3.1.1.2. Viral Vectors
3.1.1.2.1. Retro Viral Vectors
3.1.1.2.2. Adeno-associated Virus Vectors
3.1.1.2.3. Others Viral Vectors
3.2. Global Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Neurological Diseases
3.2.1.2. Cancer
3.2.1.3. DMD (Duchenne Muscular Dystrophy)
3.2.1.4. Hepatological Diseases
3.2.1.5. Other Indications
3.3. Global Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. In Vivo
3.3.1.2. Ex Vivo
3.4. Global Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
3.4.1. Key Highlights
3.4.1.1. Offline Sales Channel
3.4.1.1.1. Supermarkets/Hypermarkets
3.4.1.1.2. Departmental Stores
3.4.1.1.3. Convenience Store
3.4.1.1.4. Other
3.4.1.2. Online Sales Channel
3.4.1.2.1. Company Website
3.4.1.2.2. E-commerce Platform
3.5. Global Gene Therapy Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Gene Therapy Market Outlook, 2018 - 2030
4.1. North America Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Non-viral Vectors
4.1.1.1.1. Oligonucleotides
4.1.1.1.2. Other Non-viral Vectors
4.1.1.2. Viral Vectors
4.1.1.2.1. Retro Viral Vectors
4.1.1.2.2. Adeno-associated Virus Vectors
4.1.1.2.3. Others Viral Vectors
4.2. North America Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Neurological Diseases
4.2.1.2. Cancer
4.2.1.3. DMD (Duchenne Muscular Dystrophy)
4.2.1.4. Hepatological Diseases
4.2.1.5. Other Indications
4.3. North America Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. In Vivo
4.3.1.2. Ex Vivo
4.4. North America Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
4.4.1. Key Highlights
4.4.1.1. Offline Sales Channel
4.4.1.1.1. Supermarkets/Hypermarkets
4.4.1.1.2. Departmental Stores
4.4.1.1.3. Convenience Store
4.4.1.1.4. Other Sales Channel
4.4.1.2. Online Sales Channel
4.4.1.2.1. Company Website
4.4.1.2.2. E-commerce Platform
4.5. North America Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
4.5.1. Key Highlights
4.5.1.1. U.S. Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
4.5.1.2. U.S. Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
4.5.1.3. U.S. Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
4.5.1.4. U.S. Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
4.5.1.5. Canada Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
4.5.1.6. Canada Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
4.5.1.7. Canada Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
4.5.1.8. Canada Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Gene Therapy Market Outlook, 2018 - 2030
5.1. Europe Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Non-viral Vectors
5.1.1.1.1. Oligonucleotides
5.1.1.1.2. Other Non-viral Vectors
5.1.1.2. Viral Vectors
5.1.1.2.1. Retro Viral Vectors
5.1.1.2.2. Adeno-associated Virus Vectors
5.1.1.2.3. Others Viral Vectors
5.2. Europe Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Neurological Diseases
5.2.1.2. Cancer
5.2.1.3. DMD (Duchenne Muscular Dystrophy)
5.2.1.4. Hepatological Diseases
5.2.1.5. Other Indications
5.3. Europe Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. In Vivo
5.3.1.2. Ex Vivo
5.4. Europe Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
5.4.1. Key Highlights
5.4.1.1. Offline Sales Channel
5.4.1.1.1. Supermarkets/Hypermarkets
5.4.1.1.2. Departmental Stores
5.4.1.1.3. Convenience Store
5.4.1.1.4. Other Sales Channel
5.4.1.2. Online Sales Channel
5.4.1.2.1. Company Website
5.4.1.2.2. E-commerce Platform
5.5. Europe Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
5.5.1. Key Highlights
5.5.1.1. Germany Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
5.5.1.2. Germany Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
5.5.1.3. Germany Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
5.5.1.4. Germany Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
5.5.1.5. U.K. Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
5.5.1.6. U.K. Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
5.5.1.7. U.K. Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
5.5.1.8. U.K. Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
5.5.1.9. France Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
5.5.1.10. France Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
5.5.1.11. France Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
5.5.1.12. France Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
5.5.1.13. Italy Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
5.5.1.14. Italy Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
5.5.1.15. Italy Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
5.5.1.16. Italy Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
5.5.1.17. Turkey Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
5.5.1.18. Turkey Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
5.5.1.19. Turkey Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
5.5.1.20. Turkey Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
5.5.1.21. Russia Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
5.5.1.22. Russia Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
5.5.1.23. Russia Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
5.5.1.24. Russia Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
5.5.1.25. Rest of Europe Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
5.5.1.26. Rest of Europe Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
5.5.1.27. Rest of Europe Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
5.5.1.28. Rest of Europe Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Gene Therapy Market Outlook, 2018 - 2030
6.1. Asia Pacific Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Non-viral Vectors
6.1.1.1.1. Oligonucleotides
6.1.1.1.2. Other Non-viral Vectors
6.1.1.2. Viral Vectors
6.1.1.2.1. Retro Viral Vectors
6.1.1.2.2. Adeno-associated Virus Vectors
6.1.1.2.3. Others Viral Vectors
6.2. Asia Pacific Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Neurological Diseases
6.2.1.2. Cancer
6.2.1.3. DMD (Duchenne Muscular Dystrophy)
6.2.1.4. Hepatological Diseases
6.2.1.5. Other Indications
6.3. Asia Pacific Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. In Vivo
6.3.1.2. Ex Vivo
6.4. Asia Pacific Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
6.4.1. Key Highlights
6.4.1.1. Offline Sales Channel
6.4.1.1.1. Supermarkets/Hypermarkets
6.4.1.1.2. Departmental Stores
6.4.1.1.3. Convenience Store
6.4.1.1.4. Other Sales Channel
6.4.1.2. Online Sales Channel
6.4.1.2.1. Company Website
6.4.1.2.2. E-commerce Platform
6.5. Asia Pacific Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
6.5.1. Key Highlights
6.5.1.1. China Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
6.5.1.2. China Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
6.5.1.3. China Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
6.5.1.4. China Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
6.5.1.5. Japan Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
6.5.1.6. Japan Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
6.5.1.7. Japan Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
6.5.1.8. Japan Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
6.5.1.9. South Korea Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
6.5.1.10. South Korea Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
6.5.1.11. South Korea Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
6.5.1.12. South Korea Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
6.5.1.13. India Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
6.5.1.14. India Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
6.5.1.15. India Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
6.5.1.16. India Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
6.5.1.17. Southeast Asia Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
6.5.1.18. Southeast Asia Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
6.5.1.19. Southeast Asia Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
6.5.1.20. Southeast Asia Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
6.5.1.21. Rest of Asia Pacific Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
6.5.1.22. Rest of Asia Pacific Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
6.5.1.23. Rest of Asia Pacific Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
6.5.1.24. Rest of Asia Pacific Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Gene Therapy Market Outlook, 2018 - 2030
7.1. Latin America Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Non-viral Vectors
7.1.1.1.1. Oligonucleotides
7.1.1.1.2. Other Non-viral Vectors
7.1.1.2. Viral Vectors
7.1.1.2.1. Retro Viral Vectors
7.1.1.2.2. Adeno-associated Virus Vectors
7.1.1.2.3. Others Viral Vectors
7.2. Latin America Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Neurological Diseases
7.2.1.2. Cancer
7.2.1.3. DMD (Duchenne Muscular Dystrophy)
7.2.1.4. Hepatological Diseases
7.2.1.5. Other Indications
7.3. Latin America Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. In Vivo
7.3.1.2. Ex Vivo
7.4. Latin America Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
7.4.1. Key Highlights
7.4.1.1. Offline Sales Channel
7.4.1.1.1. Supermarkets/Hypermarkets
7.4.1.1.2. Departmental Stores
7.4.1.1.3. Convenience Store
7.4.1.1.4. Other Sales Channel
7.4.1.2. Online Sales Channel
7.4.1.2.1. Company Website
7.4.1.2.2. E-commerce Platform
7.5. Latin America Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
7.5.1. Key Highlights
7.5.1.1. Brazil Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
7.5.1.2. Brazil Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
7.5.1.3. Brazil Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
7.5.1.4. Brazil Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
7.5.1.5. Mexico Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
7.5.1.6. Mexico Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
7.5.1.7. Mexico Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
7.5.1.8. Mexico Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
7.5.1.9. Argentina Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
7.5.1.10. Argentina Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
7.5.1.11. Argentina Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
7.5.1.12. Argentina Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
7.5.1.13. Rest of Latin America Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
7.5.1.14. Rest of Latin America Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
7.5.1.15. Rest of Latin America Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
7.5.1.16. Rest of Latin America Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Gene Therapy Market Outlook, 2018 - 2030
8.1. Middle East & Africa Gene Therapy Market Outlook, by Vectors, Value (US$ Bn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Non-viral Vectors
8.1.1.1.1. Oligonucleotides
8.1.1.1.2. Other Non-viral Vectors
8.1.1.2. Viral Vectors
8.1.1.2.1. Retro Viral Vectors
8.1.1.2.2. Adeno-associated Virus Vectors
8.1.1.2.3. Others Viral Vectors
8.2. Middle East & Africa Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Neurological Diseases
8.2.1.2. Cancer
8.2.1.3. DMD (Duchenne Muscular Dystrophy)
8.2.1.4. Hepatological Diseases
8.2.1.5. Other Indications
8.3. Middle East & Africa Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. In Vivo
8.3.1.2. Ex Vivo
8.4. Middle East & Africa Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2030
8.4.1. Key Highlights
8.4.1.1. Offline Sales Channel
8.4.1.1.1. Supermarkets/Hypermarkets
8.4.1.1.2. Departmental Stores
8.4.1.1.3. Convenience Store
8.4.1.1.4. Other Sales Channel
8.4.1.2. Online Sales Channel
8.4.1.2.1. Company Website
8.4.1.2.2. E-commerce Platform
8.5. Middle East & Africa Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
8.5.1. Key Highlights
8.5.1.1. GCC Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
8.5.1.2. GCC Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
8.5.1.3. GCC Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
8.5.1.4. GCC Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
8.5.1.5. South Africa Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
8.5.1.6. South Africa Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
8.5.1.7. South Africa Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
8.5.1.8. South Africa Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
8.5.1.9. Egypt Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
8.5.1.10. Egypt Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
8.5.1.11. Egypt Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
8.5.1.12. Egypt Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
8.5.1.13. Nigeria Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
8.5.1.14. Nigeria Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
8.5.1.15. Nigeria Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
8.5.1.16. Nigeria Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
8.5.1.17. Rest of Middle East & Africa Gene Therapy Market by Vectors, Value (US$ Bn), 2018 - 2030
8.5.1.18. Rest of Middle East & Africa Gene Therapy Market Indication, Value (US$ Bn), 2018 - 2030
8.5.1.19. Rest of Middle East & Africa Gene Therapy Market Delivery Method, Value (US$ Bn), 2018 - 2030
8.5.1.20. Rest of Middle East & Africa Gene Therapy Market Sales Channel, Value (US$ Bn), 2018 - 2030
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs Vector Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Merck KGaA
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Novartis AG
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. AstraZeneca Plc.
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. BIOCAD
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Crinetics Pharmaceuticals Inc.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. EffRx Pharmaceuticals S.A.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Euroscreen S.A.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Vicore Pharma AB
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Bristol-Myers Squibb
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Cell Genesys Inc.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Adaptimmune Therapeutics plc.
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Achieve Life Science Inc.
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. BioCanCell Ltd.
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
9.4.14. Genelux Corporation
9.4.14.1. Company Overview
9.4.14.2. Product Portfolio
9.4.14.3. Financial Overview
9.4.14.4. Business Strategies and Development
9.4.15. Advantagene Inc.
9.4.15.1. Company Overview
9.4.15.2. Product Portfolio
9.4.15.3. Financial Overview
9.4.15.4. Business Strategies and Development
9.4.16. GenVec Inc
9.4.16.1. Company Overview
9.4.16.2. Product Portfolio
9.4.16.3. Financial Overview
9.4.16.4. Business Strategies and Development
9.4.17. GlaxoSmithKline PLC
9.4.17.1. Company Overview
9.4.17.2. Product Portfolio
9.4.17.3. Financial Overview
9.4.17.4. Business Strategies and Development
9.4.18. Amgen Inc.
9.4.18.1. Company Overview
9.4.18.2. Product Portfolio
9.4.18.3. Financial Overview
9.4.18.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations